← All themes

Immunotherapy & Oncology

Cancer treatment has moved from poisoning dividing cells towards directing the immune system at the tumour, and towards drugs that carry their payload only to cancerous tissue. It absorbs more drug development spending than any other area.

388 stocks

#	Name	Funds holding	Growth	Growth %	Fund value
51	51 AnaptysBio ANAB $1.4B	213	+5	+2%	$2.05B
52	52 Enliven Therapeutics ELVN $2.88B	212	+42	+25%	$4.06B
53	53 Nurix Therapeutics NRIX $2.59B	211	+15	+8%	$2.84B
54	54 Precigen PGEN $2.64B	210	+4	+2%	$799M
55	55 Allogene Therapeutics ALLO $449M	209	0	0%	$652M
56	56 Xencor XNCR $1.74B	208	+5	+2%	$1.36B
57	57 Immunome IMNM $2.03B	202	0	0%	$2.5B
58	58 Zymeworks ZYME $1.78B	202	-10	-5%	$1.79B
59	59 Arvinas ARVN $446M	201	-6	-3%	$469M
60	60 Replimune Group REPL $1.07B	199	+19	+11%	$1.06B
61	61 Janux Therapeutics JANX $1.05B	197	+7	+4%	$933M
62	62 Myriad Genetics MYGN $397M	196	-7	-3%	$508M
63	63 SELLAS Life Sciences SLS $2.4B	193	+33	+21%	$1.08B
64	64 UroGen Pharma URGN $1.79B	190	+17	+10%	$1.56B
65	65 Olema Pharmaceuticals OLMA $595M	185	-10	-5%	$1.28B
66	66 Cullinan Oncology CGEM $878M	183	+9	+5%	$1.3B
67	67 Oric Pharmaceuticals ORIC $1.2B	180	-2	-1%	$1.34B
68	68 CytomX Therapeutics CTMX $486M	178	-1	-0.6%	$799M
69	69 Castle Biosciences CSTL $1.01B	176	-10	-5%	$654M
70	70 Corvus Pharmaceuticals CRVS $789M	173	+9	+5%	$1.06B
71	71 Bicara Therapeutics BCAX $1.15B	171	+26	+18%	$2.07B
72	72 Tyra Biosciences TYRA $1.29B	168	+4	+2%	$2.22B
73	73 Inhibrx INBX $1.25B	162	+27	+20%	$1.36B
74	74 Puma Biotechnology PBYI $527M	160	+3	+2%	$314M
75	75 Personalis PSNL $1.7B	158	+18	+13%	$1.14B